DrugDev eConsent (electronic informed consent) technology creates more informed patients, eliminates paperwork, simplifies remote monitoring, and ensures complete transparency for regulatory audits.
King of Prussia, PA (PRWEB) December 12, 2016
Sponsors and CROs who cling to outmoded paper consent processes take a tremendous risk: 10-15% of audit findings relate to informed consent.
Join DrugDev for a live webinar December 14, 11am-12pm EST as DrugDev eConsent experts Eric Delente and Susan Brink DrPH review the current state of eConsent (electronic informed consent), offer actionable advice, and give a brief demo of pharma’s gold standard eConsent solution which is part of the unified DrugDev technology platform. (DrugDev acquired SecureConsent, the company behind DrugDev’s eConsent technology, last month. You can read the news release here.)
Webinar: DrugDev eConsent – Putting “Informed” Back into Patient Consent
Date: December 14, 2016
Time: 11:00am-12:00pm EST
Click to register.
This webinar is complimentary
Draft FDA guidance and patient advocacy groups are driving adoption of eConsent (electronic informed consent) because it makes the consenting process more efficient and effective for staff, sponsors, monitors – and most important, patients. eConsent experts Eric Delente and Susan Brink DrPH will show and tell attendees how this revolutionary technology helps pharma sponsors and CROs:
- Ensure consistent messaging for all patients
- Solve common challenges such as multiple languages and version control
- Improve patient retention through increased comprehension and satisfaction
- Manage real-time biosample consent
- Comply with global requirements
DrugDev’s fully validated eConsent solution was further developed in DrugDev’s Innovation Lab under the guidance of Executive Chair Hugo Stephenson MD. It gives sites and patients the ability to use attractive technology on virtually any mobile device including BYOD. It focuses patient attention with features including educational videos, audio narration and easy-to-understand documents and a glossary.
About the Speakers
Eric Delente, President, DrugDev Patient Solutions – Eric is recognized throughout the pharma industry for his thorough understanding of educational technology and his passion to improve the clinical trial process by better informing patients. He has been designing, developing, hosting and maintaining award-winning education portals for healthcare and science organizations for more than 20 years, most recently at Secure Consent (acquired by DrugDev). eConsent groundbreaking product lines created by Eric are the result of years of deep research, regulatory alignment and testing. These systems are being deployed successfully in dozens of studies worldwide.
Susan Brink DrPH, Strategic Advisor, DrugDev Patient Solutions – Susan is an expert in self-care and decision-making for patients, continuing education for health care providers, and health education for children. She teamed with Eric Delente to develop online informed consent for clinical trials. As the PI for the Phase I and II SBIRs Susan led the team in conducting formative research, determining patient and clinician needs, formulating intervention and evaluating the use of the resulting eConsent with patients and lay persons. Susan has served as faculty at the Pediatrics Dept. at the University of Texas Medical Branch in Galveston TX, and at the University of Texas School of Public Health.
For more on how DrugDev eConsent is revolutionizing the informed consent process read what top industry editors are saying about the DrugDev Site eConsent solution in the Philadelphia Business Journal, Clinical Leader, Clinical Informatics News, and CenterWatch.
DrugDev’s unified clinical suite enables sponsors, CROs and sites to do more trials through industry-wide collaboration, standardization and a beautiful technology experience. Featuring solutions for global site payments, site identification and activation, workflow optimization, learning management, and site and patient engagement, DrugDev helps companies transform the quality and efficiency of clinical trials from startup through closeout. The company also powers the revolutionary TransCelerate Investigator Registry and Investigator Databank collaborations with the universal identifier known as the DrugDev Golden Number. Learn more at http://www.drugdev.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/2016/12/prweb13917954.htm